Loss of immune tolerance to IL-2 in type 1 diabetes

Nature Communications

Volumn 7, Issue , 2016, Pages

  Pérol, Louis ^a,b,c,d,e   Lindner, John M ^f   Caudana, Pamela ^d,e   Nunez, Nicolas Gonzalo ^d,e   Baeyens, Audrey ^a,b,c   Valle, Andrea ^g   Sedlik, Christine ^d,e   Loirat, Delphine ^e   Boyer, Olivier ^c,h,i   Créange, Alain ^j,k   Cohen, José Laurent ^j,k,l   Rogner, Ute Christine ^b   Yamanouchi, Jun ^m   Marchant, Martine ^f   Leber, Xavier Charles ^f   Scharenberg, Meike ^f   Gagnerault, Marie Claude ^n,o,p   Mallone, Roberto ^n,o,p   Battaglia, Manuela ^g   Santamaria, Pere ^m,q   Hartemann, Agnès ^a,r   Traggiai, Elisabetta ^f   Piaggio, Eliane ^a,b,c,d,e   more..

^a SORBONNE UNIVERSITÉ   (France)

^b CNRS   (France)

^c INSERM   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e INSTITUT CURIE   (France)

^f NOVARTIS PHARMA AG   (Switzerland)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h NORMANDIE UNIVERSITÉ   (France)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^l INSERM U955   (France)

^m UNIVERSITY OF CALGARY   (Canada)

ⁿ INSTITUT COCHIN   (France)

^o Institut Cochin   (France)

^p UNIVERSITÉ PARIS DESCARTES   (France)

^q INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^r HÔPITAL CHARLES FOIX   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; INSULIN; INTERLEUKIN 2; INTERLEUKIN 2 AUTOANTIBODY; UNCLASSIFIED DRUG; IL2 PROTEIN, HUMAN; PEPTIDE;

ANTIBODY; ANTIGEN; BLOOD; CELLS AND CELL COMPONENTS; DIABETES; DISEASE INCIDENCE; HORMONE; IMMUNE RESPONSE; PROTEIN; RODENT;

ADULT; AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GERMINAL CENTER; HUMAN; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEMORY CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; SOMATIC HYPERMUTATION; T LYMPHOCYTE; ADOLESCENT; AGED; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CYTOLOGY; IMMUNOLOGY; MIDDLE AGED; NONOBESE DIABETIC MOUSE; PANCREAS; VERY ELDERLY; YOUNG ADULT;

MUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; EPITOPES; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; INTERLEUKIN-2; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MIDDLE AGED; PANCREAS; PEPTIDES; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84990866020     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13027     Document Type: Article

References (36)

1. Browne, S. K. Anticytokine autoantibody-associated immunodeficiency. Ann. Rev. immunol. 32, 635-657 (2014).
2. Piccoli, L. et al. Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat. commun. 6, 7375 (2015).
3. Malek, T. R. The biology of interleukin-2. Ann. rev. immunol. 26, 453-479 (2008).
4. Bach, J. F. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr. rev. 15, 516-542 (1994).
5. Herold, K. C., Vignali, D. A., Cooke, A. & Bluestone, J. A. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat. rev. Immunol. 13, 243-256 (2013).
6. Anderson, M. S. & Bluestone, J. A. The NOD mouse: a model of immune dysregulation. Ann. rev. immunol. 23, 447-485 (2005).
7. Concannon, P., Rich, S. S. & Nepom, G. T. Genetics of type 1A diabetes. N. Engl. j. med. 360, 1646-1654 (2009).
8. Grinberg-Bleyer, Y. et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. exp. med. 207, 1871-1878 (2010).
9. Baeyens, A. et al. Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. Diabetes 62, 3120-3131 (2013).
10. Lo, B. et al. Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status. J. transl. med. 9, 203 (2011).
11. Michel, C., Boitard, C. & Bach, J. F. Insulin autoantibodies in non-obese diabetic (NOD) mice. Clin. exp. immunol. 75, 457-460 (1989).
12. Yamanouchi, J. et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. genet. 39, 329-337 (2007).
13. Rogner, U. C., Boitard, C., Morin, J., Melanitou, E. & Avner, P. Three loci on mouse chromosome 6 influence onset and final incidence of type I diabetes in NOD.C3H congenic strains. Genomics 74, 163-171 (2001).
14. Liston, A., Siggs, O. M. & Goodnow, C. C. Tracing the action of IL-2 in tolerance to islet-specific antigen. Immunol. cell biol. 85, 338-342 (2007).
15. Elgueta, R., de Vries, V. C. & Noelle, R. J. The immortality of humoral immunity. Immunol. rev. 236, 139-150 (2010).
16. Skowera, A. et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. clin. invest. 118, 3390-3402 (2008).
17. Judkowski, V. et al. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J. immunol. 166, 908-917 (2001).
18. Huang, J. et al. Isolation of human monoclonal antibodies from peripheral blood B cells. Nat. protoc. 8, 1907-1915 (2013).
19. Martinuzzi, E. et al. acDCs enhance human antigen-specific T-cell responses. Blood 118, 2128-2137 (2011).
20. Kamanaka, M. et al. Amino acid polymorphisms altering the glycosylation of IL-2 do not protect from type 1 diabetes in the NOD mouse. Proc. Natl Acad. Sci. USA 106, 11236-11240 (2009).
21. Long, S. A. et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 59, 407-415 (2010).
22. Long, S. A. et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 61, 2340-2348 (2012).
23. Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 1, 295-305 (2013).
24. Saadoun, D. et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. j. med. 365, 2067-2077 (2011).
25. Monti, E. et al. Purification of interleukin-2 antibodies from healthy individuals. Immunol. lett. 36, 261-266 (1993).
26. Prochazka, M., Serreze, D. V., Frankel, W. N. & Leiter, E. H. NOR/Lt mice: MHC-matched diabetes-resistant control strain for NOD mice. Diabetes 41, 98-106 (1992).
27. Tan, E. M. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis rheum. 25, 1271-1277 (1982).
28. Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis rheum. 31, 315-324 (1988).
29. Vitali, C. et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. rheum. dis. 61, 554-558 (2002).
30. Troyanov, Y. et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84, 231-249 (2005).
31. Benveniste, O. et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis rheum. 63, 1961-1971 (2011).
32. Polman, C. H. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann. neurol. 58, 840-846 (2005).
33. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J. Peripher. Nerv. Syst. 15, 1-9 (2010).
34. Mallone, R. et al. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin. Exp. immunol. 163, 33-49 (2011).
35. Mallone, R. et al. CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes 56, 613-621 (2007).
36. Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687-697 (2008).